Soleno Therapeutics Return on Equity

Soleno Therapeutics (SLNO) currently reports a ROE of 19.37%. That is above the Healthcare sector average of 11.15%. Use the charts on this page to explore Soleno Therapeutics's ROE history and peer comparisons.

Soleno Therapeutics's ROE of 19.37% is higher than the Healthcare sector average of 11.15%. That is roughly 73.7% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Soleno Therapeutics's current 19.37% should be judged against Healthcare norms (sector average: 11.15%) and against SLNO's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of 19.37%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 11.15%. From there, open related valuation or income-statement pages for Soleno Therapeutics, and consider following SLNO for alerts when major investors trade the stock.

Soleno Therapeutics is classified in the Healthcare sector. On ROE, it currently shows 19.37% versus a sector average near 11.15%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing SLNO with unrelated industries.